Bills › 2025-26
2SHB 2145: 340B drug pricing program
Data last updated: bill actions through Aug 23, 2026 · lobbyist reports through Sep 30, 2026 (read Oct 14, 2026)
Protecting patient access to discounted medications and health care services through Washington's health care safety net by preventing manufacturer limitations on the 340B drug pricing program.
- Prime sponsor
- My-Linh Thai
- Introduced
- Feb 9, 2026
- Status
- Referred to Rules 2 Review. (Feb 9, 2026)
- The Legislature's page
- 2SHB 2145 on leg.wa.gov
Floor votes
No floor roll call on file (it didn't pass a chamber, or it was decided without one).
Who lobbied on it 25
| Employer | Lobbyists | To 2026 candidates |
|---|---|---|
| PHARMACEUTICAL RSRCH/MFG OF AMERICA | 4 | — |
| WA ST HOSPITAL ASSN | 3 | — |
| WA ASSN FOR COMMUNITY HEALTH | 2 | — |
| ABBVIE INC | 1 | — |
| AIDS Healthcare Foundation | 1 | — |
| AMGEN INC | 1 | — |
| BRISTOL-MYERS SQUIBB CO | 1 | $26,350 |
| BUILDING INDUSTRY ASSN OF WA | 1 | — |
| ELI LILLY & COMPANY | 1 | $28,450 |
| GENENTECH | 1 | $13,000 |
| GENENTECH (contracted through KATHRYN KOLAN) | 1 | — |
| GILEAD SCIENCES INC | 1 | $51,200 |
| GLAXO SMITHKLINE | 1 | — |
| HEALTHCARE DISTRIBUTION ALLIANCE c/o MultiState Associates LLC | 1 | — |
| JOHNSON & JOHNSON SERVICES, INC. | 1 | $3,600 |
| Lundbeck Pharmaceuticals LLC | 1 | — |
| NATL FEDERATION OF INDEPENDENT BUSINESS | 1 | — |
| Novartis Services, Inc. | 1 | $3,000 |
| Novartis Services, Inc. (contracted through ROMAN M DANIELS-BROWN) | 1 | — |
| PFIZER INC | 1 | $32,300 |
| Prime Therapeutics, LLC | 1 | — |
| SANOFI US | 1 | — |
| TAKEDA PHARMACEUTICALS AMERICA, INC. (contracted through ROMAN M DANIELS-BROWN) | 1 | — |
| WA Hospitality Assn | 1 | $39,600 |
| WA ST PHARMACY ASSN | 1 | — |
Lobbying reports name a bill number, not a position on it or a version of it. Money: what each employer (as a donor to two or more 2026 candidates) gave to the 2026 campaigns of the members who voted yea or nay on the bill's latest final passage in each chamber.